Revolutionizing Preventive Healthcare with AI and Robotics
July 12, 2024, 9:49 pm
In a groundbreaking move, AIRS Medical has secured $20 million in Series C funding to propel their AI-powered preventive healthcare solutions to new heights. This investment, led by BSK Investment and Shinyoung Securities, signifies a strong vote of confidence in AIRS Medical's flagship product, SwiftMR™, and their overarching mission to revolutionize healthcare through technological innovation.
SwiftMR™, a cutting-edge solution harnessing deep learning technology, has been designed to enhance MRI scan speeds by an impressive 50% compared to traditional methods. This remarkable advancement has translated into a 38% increase in patient throughput and a 22% reduction in business hours for radiology centers and hospitals that have integrated SwiftMR™. The financial benefits are equally significant, with an average of $44,000 in additional revenue per month and an $8,000 reduction in monthly operating costs.
The impact of SwiftMR™ extends beyond mere efficiency gains. By providing whole pulse-sequence coverage and true super resolution, this technology has set a new standard in diagnostic imaging. It addresses critical challenges faced by radiology centers and hospitals, such as long patient wait times and the downstream effects of delayed diagnoses.
One of the most pressing issues in healthcare is the delayed diagnosis of patients, often leading to worsened outcomes due to resource shortages. AIRS Medical is at the forefront of a paradigm shift, aiming to proactively detect diseases before they manifest. Through the integration of AI and robotics, AIRS Medical is democratizing access to top-tier diagnostics and prognostics, reducing costs, and making MRI scans more accessible. This proactive approach empowers patients with conditions like dementia, stroke, and cancer to receive early diagnoses, significantly improving their chances of better health outcomes.
As part of their commitment to delivering high-quality preventive care to all, AIRS Medical has been rapidly expanding its reach. Initially launched in Korea in 2021, SwiftMR™ has successfully penetrated the markets in the United States and Europe by 2023, now accounting for over half of the company's annual recurring revenue. CEO Hyeseong Lee expressed gratitude for the substantial support from investors, emphasizing that this funding will enable AIRS Medical to broaden access to preventive healthcare services globally, fostering a healthier future for individuals worldwide.
With the infusion of this latest round of funding, AIRS Medical is poised to accelerate its growth trajectory and push the boundaries of innovation beyond the award-winning SwiftMR™. The company's strategic plans include expanding its presence in international markets, investing in research and development, and ultimately enhancing patient outcomes on a global scale.
In conclusion, AIRS Medical's relentless pursuit of excellence in preventive healthcare through AI and robotics is not only transforming the landscape of healthcare but also paving the way for a future where early detection and proactive interventions become the norm, ensuring better health outcomes for all.
SwiftMR™, a cutting-edge solution harnessing deep learning technology, has been designed to enhance MRI scan speeds by an impressive 50% compared to traditional methods. This remarkable advancement has translated into a 38% increase in patient throughput and a 22% reduction in business hours for radiology centers and hospitals that have integrated SwiftMR™. The financial benefits are equally significant, with an average of $44,000 in additional revenue per month and an $8,000 reduction in monthly operating costs.
The impact of SwiftMR™ extends beyond mere efficiency gains. By providing whole pulse-sequence coverage and true super resolution, this technology has set a new standard in diagnostic imaging. It addresses critical challenges faced by radiology centers and hospitals, such as long patient wait times and the downstream effects of delayed diagnoses.
One of the most pressing issues in healthcare is the delayed diagnosis of patients, often leading to worsened outcomes due to resource shortages. AIRS Medical is at the forefront of a paradigm shift, aiming to proactively detect diseases before they manifest. Through the integration of AI and robotics, AIRS Medical is democratizing access to top-tier diagnostics and prognostics, reducing costs, and making MRI scans more accessible. This proactive approach empowers patients with conditions like dementia, stroke, and cancer to receive early diagnoses, significantly improving their chances of better health outcomes.
As part of their commitment to delivering high-quality preventive care to all, AIRS Medical has been rapidly expanding its reach. Initially launched in Korea in 2021, SwiftMR™ has successfully penetrated the markets in the United States and Europe by 2023, now accounting for over half of the company's annual recurring revenue. CEO Hyeseong Lee expressed gratitude for the substantial support from investors, emphasizing that this funding will enable AIRS Medical to broaden access to preventive healthcare services globally, fostering a healthier future for individuals worldwide.
With the infusion of this latest round of funding, AIRS Medical is poised to accelerate its growth trajectory and push the boundaries of innovation beyond the award-winning SwiftMR™. The company's strategic plans include expanding its presence in international markets, investing in research and development, and ultimately enhancing patient outcomes on a global scale.
In conclusion, AIRS Medical's relentless pursuit of excellence in preventive healthcare through AI and robotics is not only transforming the landscape of healthcare but also paving the way for a future where early detection and proactive interventions become the norm, ensuring better health outcomes for all.